Articles tagged with Immunotherapy
A team of researchers led by Dr. Michele Ardolino is bridging scientific fields to unlock the mechanisms behind effective immune responses in cancer patients. They will study the interactions between the immune system, nervous system, and gut microbiome to design more personalized treatment strategies.
Researchers have presented a comprehensive review on synergistic ferroptosis–immunotherapy nanoplatforms to overcome TME resistance and enhance antitumor immunity. The work offers a systematic roadmap for integrating ferroptosis induction with immunotherapy.
A study reveals how colorectal tumors use TGF-β to prevent immune cells from reaching and attacking the tumor. The researchers suggest strategies to improve immunotherapy efficacy by blocking this dual barrier and identifying new therapeutic targets.
Researchers at MD Anderson Cancer Center are sharing new insights on training the immune system to improve patient outcomes. Key findings include the potential of gut microbiome manipulation in improving immunotherapy responses and developing novel treatments for patients with EGFR-positive lung cancer.
A new biomaterial platform induces local accumulation of immune cells, forming structures similar to those found in tumors. This model could lead to therapies that stimulate TLS formation and boost antitumor immunity.
Researchers at University of Texas M. D. Anderson Cancer Center discover that inflammation is responsible for driving the earliest stages of lung cancer, identifying potential targets for early intervention and suggesting a promising approach to intercepting lung cancer development.
Researchers have identified a distinct population of neuroprotective microglia that may point to a new therapeutic approach for Alzheimer's disease. Microglia with reduced expression of PU.1 and co-expression of CD28 limit neuroinflammation and slow amyloid plaque build-up.
Researchers identified a PU.1-promoting subset of microglia that suppresses inflammation and protects cognitive function in mice with Alzheimer's disease. This discovery opens a new avenue for immunotherapies targeting microglial activity.
MIT researchers use messenger RNA to activate an immune pathway in nearby immune cells, triggering the destruction of tumors. The approach combines existing immunotherapy drugs and avoids side effects associated with large doses of STING activators.
Researchers at Northwestern University have discovered how pancreatic tumors evade the immune system and created an antibody therapy that blocks this mechanism, reawakening immune cells to attack cancer cells. The study shows promise for treating pancreatic cancer and may have broader implications for other hard-to-treat cancers.
Researchers at Monash University have developed a new strategy to improve CAR T cell therapy for solid tumors. By targeting the PTPN2 protein, they enhanced the efficacy of CAR T cells and generated long-lived memory T cells that can persist in circulation.
A UCLA study finds that DNA copy-number changes enable melanoma cells to resist immune attacks, leading to tumor relapse. The researchers suggest a strategy to make tumors more prone to self-destruction after immune attacks, potentially extending the effectiveness of immunotherapy.
Research suggests m⁶A modification regulates oncogenic pathways, immune evasion, and metabolic reprogramming in cancer. Dysregulation of m⁶A drives cancer hallmarks like uncontrolled proliferation and metastasis.
Researchers at Mayo Clinic have found a way to enhance the body's 'first responder' cells, which can boost standard immunotherapies for cancer. By targeting these myeloid cells, it may be possible to improve treatments that interfere with immune suppressive proteins PD-1 and PD-L1.
Researchers developed a computational platform to design synthetic protein receptors that can detect tumor signals and boost T cell activity. The new receptors, called T-SenSERs, showed improved tumor control and longer survival in mouse models of lung cancer and multiple myeloma.
The Allison Institute's third annual scientific symposium featured a panel discussion with five Nobel laureates, highlighting breakthroughs in cancer vaccines, immunotherapy, and immunology research. The event also recognized scientific achievement and leadership through award presentations.
A new Alliance trial is exploring the effectiveness of a combination of targeted therapy and immunotherapy for patients with advanced adrenocortical carcinoma, a rare and aggressive cancer. The study aims to improve disease control and quality of life for patients with limited treatment options.
Researchers at UCLA have developed CAR-NKT cell therapy, which can attack tumors from multiple fronts while dismantling their protective shields. The therapy uses engineered immune cells that can be mass-produced from donated blood stem cells and stored ready-to-use, offering a potentially life-changing treatment option.
A study published in the Lancet Child and Adolescent Health journal found that high-risk neuroblastoma survivors experience a high prevalence of hearing loss, growth failure, underweight, and lung disease due to modern therapies. Longer follow-up periods were associated with a higher risk of late effects.
Researchers found a targeted immunotherapy regimen yielded promising survival outcomes for patients with B-cell ALL, outperforming historical results. The treatment was well-tolerated, with more than half completing the full course of therapy, and responded similarly in patients with complex medical histories.
A new clinical trial by ECOG-ACRIN Cancer Research Group found pembrolizumab reduced cancer recurrence risk to 73% in patients receiving the treatment after surgery. Patients also showed a 42% lower risk of developing distant metastases.
Researchers discovered craters on the surface of melanoma cells that serve as immune hubs and facilitate local tumor killing. These structures, termed CRATERs, may serve as a more accurate marker of immunotherapy's success in treating solid tumors.
Researchers at MD Anderson have discovered a previously unknown mechanism that explains how bacteria can drive treatment resistance in patients with oral and colorectal cancer. The study also identifies a new biomarker for improved immunotherapy responses in solid tumors.
Researchers developed a novel technology to attach 'fake targets' to tumor cells, enabling immune cells to attack regardless of antigen presence. The Univody platform showed promising results in animal models, suppressing tumor growth and triggering broader immune activation.
A new combination therapy combining epigenetic therapy with anti-PD-1 antibody showed promising results in patients with relapsed or refractory natural killer/T-cell lymphoma. The treatment triggered viral mimicry, restoring immune sensitivity and improving survival rates.
Researchers at UMC Utrecht discovered that converting monoclonal antibodies from IgG to IgM isotype can significantly broaden their ability to recognize and bind multiple human-relevant bacterial pathogens. This finding could guide the future design of antibody therapies against bacterial infections.
Scientists at Institut Pasteur and Inserm developed a triple-therapy approach to treat blood cancers like lymphomas and leukemias. They induced necroptosis in malignant B cells, which activates the immune system to eliminate tumor cells.
A multi-institutional study found that serially testing tumor samples can detect immune system activation in recurrent glioblastoma even when traditional imaging measures cannot. The researchers used multi-omic analysis and integrated data from various sources to show positive changes in the tumor microenvironment over time.
Scientists at Fralin Biomedical Research Institute are developing nanotechnology-based approaches to reprogram the immune system and overcome tumor defenses. Integrating nanomedicine with immunology promises more precise and effective therapies.
Researchers at UCSF have discovered a novel combination of immunotherapies that can reprogram the immune environment of colon cancer tumors in the liver. This therapy often eliminated tumors entirely in preclinical models, showing promise for treating patients with advanced colorectal cancer.
Researchers at MIT have developed a new way to engineer CAR-NK cells that are less likely to be rejected by the patient's immune system, making them a promising treatment for cancer. The cells can destroy most cancer cells while evading the host immune system, and may offer a better safety profile than traditional CAR-T cells.
A newly identified antibody, 04_A06, has been found to block 98.5% of over 300 different HIV strains in laboratory tests. In humanized mice models, the antibody reduced viral load to undetectable levels, offering a promising approach for HIV prevention and treatment.
A team at Lund University has discovered a surface protein, SLAMF6, that helps leukemia cells evade the immune system. The researchers developed an antibody to block this mechanism, restoring the immune system's ability to kill cancer cells in laboratory trials and mice.
Researchers at Ohio State University have found that cancer immunotherapy fails due to a collapse in protein quality control, leading to T-cell exhaustion. This discovery offers a new avenue for cancer immune therapy development by targeting the protein production cycle.
Glypican-3 is a key driver of hepatocellular carcinoma progression, facilitating metastasis and tumor microenvironment remodeling. Immunotherapy targeting GPC3 has shown preliminary safety and antitumor activity in clinical trials, with ongoing research focusing on optimized patient selection and disease monitoring.
A phase 1B clinical trial found that combining avelumab with whole brain radiotherapy provides a safe and effective treatment option for patients with leptomeningeal disease, with 67% of patients alive three months after treatment. The study also showed an adaptive immune response to treatment, reducing levels of regulatory T cells.
Researchers developed a new strategy to boost immunotherapy in solid tumors by targeting senescent immune cells, which contribute to treatment resistance. The approach showed improved efficacy and lower toxicity compared to existing treatments.
A research team led by Professor Shikha Dhiman has discovered that the speed of receptors in model cell membranes plays a crucial role in binding to biomaterials. When ligands move at similar speeds, they can bind to receptors, enabling effective tissue engineering and medical applications.
Recent clinical trials demonstrate the potential benefits of neoadjuvant chemotherapy and immunotherapy in improving tumor response and surgical success for patients with locally advanced colon cancer. The approach also reduces the risk of recurrence and metastasis, increasing survival outcomes and decreasing cancer-related complications.
Researchers identified Wnt7b as a determinant of resistance to immune checkpoint blockers in glioblastoma and developed a combination therapy with WNT974 that sensitizes GBM to anti-PD1 therapy, improving anti-tumor immunity. This approach offers a promising new therapeutic avenue for glioblastoma patients.
Researchers from St. Jude Children's Research Hospital have made a breakthrough in treating neuroblastoma by combining immunotherapy with the drug indisulam, achieving complete therapeutic responses in laboratory models regardless of cell state.
Researchers have identified a secreted form of a protein called Clever-1 that systemically suppresses T cells essential for fighting cancer. The investigational anti-Clever-1 antibody, bexmarilimab, directly inhibits the release of sClever-1, potentially predicting treatment resistance and paving the way for new combination treatments.
Research has shown that lymph nodes provide the right environment for stem-like T cells to survive, multiply, and produce killer cells. Preserving lymph nodes could strengthen immune responses and increase the effectiveness of immunotherapy. The study's findings have important implications for cancer therapy.
Researchers are developing a novel smart coating to enable continuous monitoring of cells during CAR T-cell production, reducing production costs. The biosensor coating is expected to reduce human errors and costs associated with existing flow cytometry methods.
Researchers have found a way to use antibodies to direct T cells to kill Cytomegalovirus-infected cells, offering an alternative treatment for life-threatening infections without expensive and side-effect-prone drugs.
Researchers at UMass Amherst found that certain T-cells have an inherent ability to remember past viral foes, which could lead to next-generation cancer vaccines. This 'immunological memory' is crucial for the body's immune response and can be harnessed for targeted therapies.
Research by University of Pittsburgh scientists discovered that damaging telomeres can lead to dysfunctional T cell function. To combat this, they developed a targeted antioxidant approach that rescued T cell function, opening the door for novel therapies in cancer immunotherapies.
Researchers at NUS have developed a bioengineering approach to keep human lymph node tissue alive and functioning outside the body for several days. The method involves embedding thin slices of lymph node tissue in a soft gel that mimics the body's natural environment, allowing for detailed studies of immune cell behavior.
Adult fibrosarcoma is a rare and highly aggressive malignancy requiring precise diagnosis and multimodal treatment. The case report emphasizes the need for early detection, complete surgical removal, and tailored postoperative care to improve outcomes in patients with this type of tumor.
Researchers harness AlphaFold 3 to predict how T cells recognize peptides, opening avenues for precision immunotherapy and vaccine design. The approach enables in silico identification of immunogenic epitopes that could serve as vaccine targets.
Researchers have identified a potential new strategy for treating glioblastoma multiforme (GBM), the most common and aggressive type of adult brain cancer. Disabling a protein called ADAR1 can stall GBM cell proliferation while reprogramming the tumor microenvironment to an anti-tumoral state.
A new mitochondrial-targeting drug, LCL768, has been developed to attack head and neck cancer cells by damaging their mitochondria. The drug's ability to increase ceramide levels inside mitochondria triggers mitophagy, leading to cancer cell death.
Researchers have developed AlloCAR70-NKT, an innovative cell therapy harnessing the immune system to fight cancer. The therapy demonstrates a multi-pronged attack against kidney cancer, directly killing cells and disrupting the tumor's microenvironment.
Researchers at Lund University identify genetic toolkit to program dendritic cell subtypes for targeted cancer treatment. The discovery could lead to more precise and powerful immunotherapies by supplying patients with tailored dendritic cells.
A phase 2 clinical trial found that autologous tumor-infiltrating lymphocyte (TIL) cell therapy helped stabilize metastatic head and neck squamous cell carcinoma (HNSCC) in some patients. The median response duration was 7.6 months, with cancer stabilization occurring in 64% of patients.
A new study by Moffitt Cancer Center researchers has found that cancer-induced nerve injury weakens the effectiveness of anti-PD-1 immunotherapy. The study shows that cancer cells infiltrate and damage tumor-associated nerves, triggering an inflammatory response that ultimately suppresses the immune system's ability to fight cancer.
Researchers found that cancer cells break down nerve protective covers, triggering chronic inflammation and immune exhaustion, making treatment resistant. Targeting the nerve injury pathway can reverse this resistance and improve treatment response.
A new study from Moffitt Cancer Center found that a combination of immune-targeting drugs, including TIM-3, was effective in shrinking tumors in lab models of treatment-resistant melanoma. The triplet therapy also restored immune function and led to complete tumor regressions in some cases.
A new blood test, PIPscore, has been developed to predict the efficacy of immunotherapy in triple-negative breast cancer (TNBC) patients. The test analyzes plasma proteins and achieved high accuracy in forecasting patient responses.
Researchers developed a neoAg mRNA-based vaccine that induces higher frequency of neoAg-specific cytotoxic T cells in mice, leading to tumor regression and eradication. The combination with anti-PD-1 therapy enhances antitumor efficacy, especially against peritoneal metastasis.